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The induction of an acute inflammatory response followed by the
release of polypeptide cytokines and growth factors from periph-
eral blood monocytes has been implicated in mediating the re-
sponse to vascular injury. Because the Cu2-binding proteins IL-1
and fibroblast growth factor 1 are exported into the extracellular
compartment in a stress-dependent manner by using intracellular
Cu2 to facilitate the formation of S100A13 heterotetrameric
complexes and these signal peptideless polypeptides have been
implicated as regulators of vascular injury in vivo, we examined the
ability of Cu2 chelation to repress neointimal thickening in re-
sponse to injury. We observed that the oral administration of the
Cu2 chelator tetrathiomolybdate was able to reduce neointimal
thickening after balloon injury in the rat. Interestingly, although
immunohistochemical analysis of control neointimal sections ex-
hibited prominent staining for MAC1, IL-1, S100A13, and the
acidic phospholipid phosphatidylserine, similar sections obtained
from tetrathiomolybdate-treated animals did not. Further, adeno-
viral gene transfer of the IL-1 receptor antagonist during vascular
injury also significantly reduced the area of neointimal thickening.
Our data suggest that intracellular copper may be involved in
mediating the response to injury in vivo by its ability to regulate
the stress-induced release of IL-1 by using the nonclassical export
mechanism employed by human peripheral blood mononuclear
cells in vitro.
phosphatidylserine  interleukin 1  restenosis  tetrathiomolybdate 
fibroblast growth factor
The elucidation of the pathways involved in the regulation ofthe vascular response to injury is critical for the management
of human diseases in which the pathology may be regulated by
stress-induced endothelial and vascular smooth muscle cell
responses. Although a variety of polypeptide growth factors and
cytokines have been implicated as mediators of the vascular
response to injury (1–5), our current understanding involves a
fundamental role for the migration of peripheral blood mono-
nuclear (PBM) cells into sites of injury as a delivery system for
these biological response modifiers as regulators of both the
inflammatory and angiogenic responses (6, 7).
Prior studies have suggested that members of the IL-1 and
fibroblast growth factor (FGF) (8, 9) gene families may signif-
icantly contribute to vessel-wall pathology in response to injury.
The IL-1 and FGF gene families are composed of at least 10 and
23 members, respectively (10–13), and membership is defined by
structural homology with the prototype members of each gene
family, namely IL-1IL-1 and FGF1FGF2. Although the
IL-1 and FGF prototypes exhibit limited primary sequence
homology (14), these prototype polypeptides are viewed as
crystallographic homologs (15). Furthermore, the IL-1 and FGF
prototypes do not contain classical signal peptide sequences to
direct their export through the endoplasmic reticulum-Golgi
apparatus (16), and although only 3 of the 23 FGF genes lack this
feature, 8 of the 10 IL-1 genes lack a classical signal peptide
sequence. Because it is well established that the IL-1 and FGF
prototypes function in the extracellular compartment as ligands
for high-affinity cell-surface receptors (11, 13), the identification
of the mechanism(s) used by the IL-1 and FGF prototypes for
nonclassical release could potentially yield new insight into
proinflammatory and angiogenic disorders.
The appearance of IL-1 and FGF1 in the extracellular
compartment is regulated by convergent yet distinct nonclassical
export pathways induced by cellular stress (17, 18). Both IL-1
(19) and FGF1 (20) use intracellular Cu2 to force the assembly
of a multiprotein complex near the inner surface of the plasma
membrane (19, 20). Although both IL-1 and FGF1 form
Cu2-dependent heterotetrameric complexes with S100A13 to
facilitate their release, the FGF1 release pathway also requires
the function of the extravesicular domain of synaptotagmin
(Syt)1 for export (21). Interestingly, the overexpression of
S100A13 overcomes the requirement for stress-induced tran-
scription for export of IL-1 (19) and FGF1 (22), and it is known
that both FGF1 (23) and IL-1 (19) exhibit molten globule
character, which may facilitate the ability of both IL-1 and
FGF1 to associate with and traverse the plasma membrane. It is
also interesting to note that IL-1, FGF1, Syt1, and S100A13 are
Cu2-binding proteins (20) and are able to associate with
phosphatidylserine (pS), an acidic phospholipid that is known to
translocate from the inner to the outer surface of the plasma
membrane (24). Further, studies in both murine NIH 3T3 cells
and human U937 cells have demonstrated that the stress-induced
IL-1 (19) and FGF1 (20) release pathways are sensitive to
inhibition by the Cu2 chelator tetrathiomolybdate (TTM),
suggesting that intracellular Cu2 may play an important role in
the regulation of these pathways in vivo.
It is well established that Cu2 is not only a potent inducer of
angiogenesis in vivo (25), but studies with arterial Cu2 cuffs and
stents have also implicated Cu2 as a promoter of the arterial
response to injury (26). Because (i) TTM has been suggested to
be efficacious in the clinical management of human cancer (27),
(ii) TTM is able to significantly inhibit NF-B activity as a
component of its antiangiogenic activity in vivo (28), and (iii)
IL-1 is an important regulator of NF-B activity (29), we
questioned whether TTM could be used to limit the recruitment
of mononuclear cells in response to vascular injury in vivo by
restricting the export of IL-1. We report that the induction of
moderate copper deficiency by the oral administration of TTM
impairs neointimal thickening and significantly reduces the
expression of IL-1 and S100A13. In addition, we used a
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monoclonal antibody that recognizes the acidic phospholipid pS
and demonstrated that TTM is also able to significantly limit the
appearance of pS after vascular injury in vivo. Last, the somatic
gene transfer of the IL-1 receptor antagonist protein (IRAP)
also significantly reduces the response to vascular injury. These
data suggest that members of the IL-1 gene family may play a
prominent role in restenosis in vivo.
Methods
Cell Culture and Immunoblot Analysis. Human PBM cells were
isolated by FicoLite density gradient centrifugation from hep-
arinized blood of healthy donors. Mononuclear cells were fur-
ther isolated by adherence on tissue-culture dishes for 2 h and
maintained in RPMI medium 1640 (Sigma) containing 10%
FBS. Mononuclear cells were activated with 10 ngml of phorbol
12-myristate 13-acetate (PMA; Sigma) for 24 h before each
experiment. Before heat shock (2 h at 42°C), the mononuclear
cells were plated on fibronectin (10 mgcm3)-coated cell-culture
dishes. Briefly, IL-1 from the conditioned medium was resolved
by Cu2-affinity chromatography (Hi Trap, Amersham Pharma-
cia), eluted with 60 mM imidazole, resolved by 15% acrylamide
SDSPAGE, and evaluated by IL-1 immunoblot analysis (17).
TTM was purchased from Sigma–Aldrich and used as described
(19, 20). Briefly, cells were incubated for 18 h at 37°C in either
the absence or presence of 250 nM TTM and subjected to heat
shock as described (19, 20).
Ceruloplasmin Levels, Surgical Procedures, Tissue Preparation, and
Adenoviral Gene Transfer. Serum ceruloplasmin was used as a
surrogate marker of copper status (27, 28, 30). The level of serum
ceruloplasmin was quantitated before the administration of
TTM as well as on the day of the injury and on the final day of
TTM delivery as described (30).
Sprague–Dawley male rats (Charles River Breeding Labora-
tories) weighing 350–450 g at 12–16 weeks of age (n  72) were
anesthetized with an i.p. injection of ketamine (100 mgkg) and
xylazine (6 mgkg), and balloon injury of the carotid artery was
performed by using a Fogarty 2F embolectomy catheter as
described (31). The animals were killed 4, 7, or 14 days post-
injury, the entire left carotid arteries were harvested and im-
mersed in either 4% formaldehyde or acetoneethanol (1:1), and
the injured carotid arteries were excised and sliced in three
sections representing the proximal, middle, and distal part of the
vessel. The specimens were dehydrated and embedded in par-
affin for sectioning, and the left carotid artery segments were
used for histological, morphometric, and immunohistochemical
studies. Evan’s blue staining of the denuded arteries was per-
formed as described (32).
For the adenoviral studies, the full-length human IRAP
cDNA with a Myc sequence at the 5 end was inserted into the
shuttle plasmid pADlox, containing the mouse cytomegalovirus
promoter, by using standard PCR techniques. A viral stock of
Ad-IRAP was plaque-purified, further propagated in 293 cells,
and purified by CsCl2 centrifugation. The concentration of
infectious viral particles was determined as described (33). The
denuded carotid artery was incubated with 100 l (2  109
plaque-forming units per ml) of Ad-IRAP (n  5) or Ad-
insertless (n  2) for 20 min. The adenovirus was removed, the
carotid artery section was flushed, and blood flow was restored.
After a follow up period of 14 days, the animals were killed after
anesthesia, and the carotid arteries were processed as described
above.
Histomorphometric Studies and Statistical Analysis. Morphometric
analysis of the arterial segment was performed in a blind manner
on cross sections stained with hematoxylineosin and orcein.
With a computerized digital microscopic planimetry algorithm
(Optimas, version 5.22), the areas within the external elastic
lamina (EEL) area, the internal elastic lamina (IEL) area, and
the luminal area were measured. Other areas were calculated as:
medial area  EEL area  IEL area; neointimal area  IEL
area  luminal area; and neointima-to-medium ratio  neoin-
timal areamedial area. All variables are expressed as the
mean  SEM, and the Student’s t test was used to examine the
differences between the experimental groups. A value of P 
0.05 was considered significant.
Generation and Characterization of Murine Monoclonal Antibody 1H6.
To generate monoclonal antibodies against pS, BALBc mice
were immunized with liposomes containing 70% pS and 30%
phosphatidylglycerol. Liposomes were resuspended in ethanol
and injected five times i.p. with an interval of 3 weeks between
injections. Hybridoma selection was performed as described
(34). Approximately 14 days postfusion, supernatants from wells
with proliferating hybrid cells were collected and tested for the
presence of anti-pS antibodies. The reactivity of the selected
antibody was established by screening hybridoma supernatants
on pS, cholesterol, phosphatidylethanolamine, and phosphati-
dylcholine (Avanti Polar Lipids) either immobilized on plastic
for analysis by ELISA or dried on a nitrocellulose membrane for
analysis by immunoblot methods.
The binding of anti-pS (monoclonal antibody 1H6) was as-
sessed on freshly isolated human platelets. Platelet-rich plasma
was obtained as described (35), and the platelets were isolated
by centrifugation and divided in two samples. The ‘‘nonactive’’
platelets were treated with 10 gml prostaglandin-1 (Sigma)
to prevent spontaneous activation, and the ‘‘active’’ platelets
were incubated with 10 nM PMA for 30 min at room temper-
ature. Both samples were fixed with ice-cold methanol and
stained with the anti-pS antibody 1H6. For control experiments,
the 1H6 antibody was preabsorbed with a 100-fold excess of pS
liposomes prepared as described (23). The labeling was visual-
ized by an anti-mouse IgG antibody conjugated to Cy3 (Molec-
ular Probes).
Immunohistochemical Analysis. To evaluate S100A13, Myc, pS, and
IL-1 expression in balloon-injured arteries, paraffin-embedded
specimens were sliced into 5-m cross sections, the paraffin was
removed with xylene washes, and the specimens were mounted
on glass slides and incubated in 10% hydrogen peroxide for 90
min to block endogenous peroxidase activity. Nonspecific bind-
ing was minimized by preincubating the sections with 5% BSA
(Sigma) in PBS. The sections were sequentially incubated with
either a rabbit anti-S100A13, a monoclonal anti-Myc (Oncogene
Science), a rabbit anti-IL-1, a monoclonal anti-platelet-
endothelial cell adhesion molecule (PECAM; DAKO), or the
affinity-purified anti-pS monoclonal antibody. After two washes
with PBS, the sections were incubated with either an anti-rabbit
or an anti-mouse IgG-conjugated horseradish peroxidase anti-
body (Bio-Rad). Staining was visualized with chromogen
(Bio-Rad). The presence of macrophages was evaluated by
immunostaining with anti-CD11b (MAC1) by using acetone
ethanol-fixed sections.
Results
Although Cu2-affinity chromatography has been used to ad-
sorb IL-1 from medium conditioned by temperature stress (19),
little is known about the ability of IL-1 to associate with Cu2.
As a result, cell lysates from PMA-treated human PBM cells
were used as a source of the precursor and mature forms of
IL-1, and Cu2-chelation affinity chromatography was used to
evaluate the ability of IL-1 to associate with Cu2. As shown in
Fig. 1A, the precursor and mature forms of IL-1 were eluted at
35 mM imidazole, suggesting that both forms of IL-1 were
able to bind Cu2 and the mature form of IL-1 is likely to
contain the domain responsible for Cu2 affinity.
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Because the release of IL-1 (19) and FGF1 (20) use S100A13
to form a Cu2-dependent heterotetramer and the Cu2 chelator
TTM is able to repress the release of FGF1 in response to
cellular stress, we evaluated whether TTM was also able to
inhibit the heat-shock-induced export of IL-1 from PMA-
treated human PBM cells in vitro. As shown in Fig. 1B, human
PBM cells are not only able to release both the precursor and
mature forms of IL-1 in response to temperature stress, but
TTM is also able to repress the release of both the precursor and
mature forms of IL-1. These data further suggest that both the
precursor and mature forms of IL-1 are susceptible to non-
classical Cu2-dependent and temperature stress-mediated ex-
port in vitro.
Because TTM is able to repress the stress-induced release of
IL-1 in vitro, and the function of proinflammatory cytokines has
been implicated as regulators of restenosis in vivo, we evaluated
whether TTM administration would be able to modify the
response to injury after balloon injury in the rat. Because TTM
is clinically administered as an oral compound (27), rats were
prefed TTM either 1 or 2 weeks before or on the day of balloon
injury. Plasma ceruloplasmin levels were monitored, and the oral
administration of TTM at a dosage of 10 mgkg was able to
rapidly reduce and sustain the plasma level of ceruloplasmin in
all TTM-treated animals at a 50% level of reduction after 1 week
and a 70–80% reduction after 2 weeks (data not shown). This
result is consistent with data in mice to prevent tumor angio-
genesis as a result of Cu2 deficiency (28). The TTM-treated rats
were subjected to balloon injury, and after 2 weeks of daily TTM
administration postinjury the animals were killed, and the extent
of neointimal thickening was evaluated. Animals not fed TTM
served as additional controls. As shown in Fig. 2 A and B, TTM
was able to repress neointimal thickening significantly when
administered 2 weeks before injury. Indeed, this reduction was
also evident, albeit to a lesser extent, in the rats fed oral TTM
either 1 week before or on the day of balloon injury (Fig. 2C).
The kinetics of the response of neointimal thickening to TTM
withdrawal was also evaluated, and interestingly, we observed a
plateau in the maximal response 6 days after the withdrawal of
TTM (Fig. 2D).
Because TTM was able to significantly impair neointimal
thickening in vivo, we evaluated whether this response was due
to its ability to inhibit the release of IL-1 in response to injury.
Thus one would anticipate that a lack of extracellular IL-1
would impair mononuclear cell infiltration into the denuded
area. Indeed, immunohistochemical analysis with the MAC1
antibody was able to resolve the presence of mononuclear cells
4 and 7 days postinjury in the controls (Fig. 3 A and C) but failed
to report the presence of these cells at these time points in the
arteries of animals pretreated with TTM for 2 weeks before
injury (Fig. 3 B and D). Because TTM is also able to repress the
stress-induced release of IL-1 (22) and S100A13 (19) in vitro,
we examined these tissues for the expression of IL-1 and
S100A13. As shown in Fig. 4, immunohistochemical analysis
revealed the presence of IL-1 (Fig. 4 A and D) and S100A13
(Fig. 4 B and E) in control arteries 2 weeks after balloon injury
but failed to resolve their presence in arteries at this time point
from rats pretreated with TTM 2 weeks before injury. A similar
response was also observed for FGF1 expression under similar
conditions, and IL-1 and FGF1 immunoblot analysis revealed
similar TTM-dependent changes (data not shown). These data
suggest that the ability of TTM to reduce neointimal thickening
may be the result of its ability to repress the expression and
potentially the release of not only IL-1 but also S100A13, the
chaperone that forms intracellular Cu2-dependent heterotet-
rameric complexes with both IL-1 (19) and FGF1 (22).
The molten globule character of FGF1 (23) and IL-1 (19)
suggest that these proteins may be endowed with the ability to
insert and traverse acidic phospholipid-rich membranes. The
transition of pS from the inner surface to the outer surface of the
plasma membrane of platelets and endothelial cells is an im-
portant component of the intrinsic coagulation system (38), and
the presence of pS on the outer surface of the plasma membrane
Fig. 1. IL-1 is a Cu2-binding protein that is released from human PBM cells in a stress- and Cu2-dependent manner. (A) Cell lysates from PMA-activated human
PBM cells (PBMC) were adsorbed to a Cu2-affinity column and eluted with an imidazole gradient (0–100 mM) as described (20). The column was stripped with
50 mM EDTA, and all fractions including the flow were resolved by 15% acrylamide SDSPAGE and evaluated by IL-1 immunoblot analysis. (B) Conditioned
medium (CM) obtained from temperature-stressed (42°C, 2 h) PMA-activated human PBM cells was processed by Cu2-affinity chromatography, and eluted
fractions were analyzed as described for A.
Fig. 2. Copper chelation reduces the formation of neointima after balloon
injury in the rat carotid artery. TTM was administered daily in a dose of 10
mgkg dissolved into 45 ml of drinking water. TTM administration started 2
weeks before the day of the injury (n 6), 1 week before the day of the injury
(n 6), and on the day of the injury (n 5). All animals were treated with TTM
for 2 weeks after balloon injury. The rats without TTM treatment served as a
control (n  5). (A) Representative cross section of the control group not
treated with TTM; sections are stained with hematoxylineosin. (Magnifica-
tion, 10.) (B) TTM administration for 2 weeks before and 2 weeks after
balloon injury. (Magnification, 10.) (C) Bar graph showing the neointima
medium (IM) ratio (mean  SEM) in all four groups of rats. (D) Bar graph
showing the neointimaratio (mean  SEM) in five groups of animals that
were treated with TTM for 2 weeks before balloon injury followed by the
withdrawal of TTM on the day of the injury or 4, 6, 8, and 10 days after balloon
injury.
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may also be an important immediate-early component of the
apoptotic program (39). We became interested in the appear-
ance of pS on the outer surface of the plasma membrane,
because pS-rich membrane structures may also represent a
window for the stress-induced export of IL-1 and FGF1.
Interestingly, we have obtained an IgG monoclonal antibody that
is able to recognize pS by both ELISA (data not shown) and
immunodot blot methods not only at reasonably low levels of the
acidic phospholipid (Fig. 4K) but also with an apparent speci-
ficity for the pS polar head group (Fig. 4J). In addition, the
anti-pS antibody is also able to recognize activated human
platelets (Fig. 4 G and H), and this staining pattern is repressed
significantly by preadsorption of the anti-pS antibody to pS
micelles (Fig. 4I). Because the transition of pS from the inner to
the outer leaflet of the plasma membrane may be involved in the
release of IL-1 (17) and FGF1 (18) and this activity may be
exaggerated by the export of IL-1 and FGF1 into the extracel-
lular compartment, we anticipated that the presence of pS may
be a useful reporter of IL-1 and FGF1 release, and TTM may
be able to attenuate this response. Indeed, as shown in Fig. 4 C
and F, animals pretreated with TTM for 2 weeks before balloon
injury, exhibit little if any staining with the anti-pS antibody 2
weeks postinjury, whereas the control animals reveal a signifi-
cant signal at this time point.
The staining pattern exhibited by the anti-pS antibody in the
control group is noteworthy because we have observed consid-
erable staining at the blood–tissue interface (Fig. 4F), a region
at which platelet deposition is known to be exaggerated (36, 37,
40). Likewise, we were surprised by the absence of pS in the
TTM-treated animals, because the data shown in Fig. 2B suggest
that the denuded area at the blood–tissue interface is sealed with
a monolayer of cells. Although reendothelialization after balloon
angioplasty in the rat is known to occur at later time points, it was
unanticipated that this cellular monolayer could have established
itself with such rapidity. Because the MAC1 (Fig. 3 B and D) and
pS (Fig. 4 C and F) staining profiles eliminated the possibility
that this monolayer could be a combination of both mononuclear
cells and platelets, we examined these tissues for the expression
of PECAM, an endothelial cell marker. As shown in Fig. 3 E and
F, although the vessels derived from the nontreated rats did not
exhibit a PECAM-positive monolayer at the blood–tissue inter-
face 2 weeks postinjury, the rats treated with TTM for 2 weeks
before injury reported a PECAM-positive staining at the blood–
tissue interface. Further, Evan’s blue staining (Fig. 3 G and H)
also exhibited considerable luminal repair in the TTM-treated
rats at this time point, which is consistent with the suggestion that
TTM administration was not only able to repress the restenotic
program but also may have enabled reendothelialization of the
denuded area with an unanticipated rapidity.
Because the administration of TTM before balloon injury
significantly attenuated the vascular response to injury, which
may involve the ability of TTM to repress the nonclassical export
of the proinflammatory cytokine, IL-1, we sought to demon-
strate independently that the repression of IL-1 may impair
restenosis in vivo. We used somatic gene transfer after balloon
angioplasty to express the IRAP gene product, because IRAP
contains a functional signal peptide sequence that would enable
Fig. 3. TTM inhibits mononuclear cell infiltration in the balloon-injured
vessels and promotes reendothelialization. (A–D) The extent of mononuclear
cell infiltration into the vessel wall was assessed at different time points (4 and
7 days) after balloon injury. Shown are photomicrographs of the rat carotid
artery stained with an anti-CD11b (MAC1) immunostaining (20) 4 days after
balloon injury in the control (A) and TTM-treated (B) groups as well as 7 days
after balloon injury in the control group (C) and TTM-treated animals (D). The
recovery of the endothelial cells in the denuded area was assessed by staining
with an anti-PECAM antibody (20) 14 days after balloon injury in the con-
trol (E) and TTM-treated (F) groups and confirmed by Evan’s blue staining
(G and H).
Fig. 4. TTM treatment decreases the level of IL-1, S100A13, and pS expres-
sion in the balloon-injured vessel wall. (A–F) Photomicrographs of rat carotid
artery 14 days after balloon injury as shown. (Magnification,20.) Tissue slices
were subjected to immunohistochemical analysis by using an anti-IL-1 anti-
body (A, TTM-treated; D, control), anti-S100A13 antibody (B, TTM-treated; E,
control), and the 1H6 antibody (C, TTM-treated; F, control). (G–I) Immunohis-
tochemical analysis of pS expression in control (G) and PMA-treated (H)
platelets with the anti-pS antibody. (I) Preadsorption of the anti-pS antibody
with pS liposomes served as an additional control. (J) The selectivity of the
anti-pS antibody was evaluated by immunoblot analysis on pS, cardiolipin
(CL), phosphatidylglycerol (pG), phosphatidylinositol (pI), and phosphatidyl-
choline (pC) immobilized on a nitrocellulose membrane. (K) The reactivity of
the anti-pS antibody was evaluated in a concentration-dependent manner by
using immunodot blot analysis with a decreasing amount of pS.
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it to have unrestricted access to the extracellular compartment
to inhibit with a high degree of specificity the proinflammatory
function of IL-1 gene family prototypes (41). We prepared an
IRAP-Myc fusion gene to evaluate the expression of IRAP after
gene transfer, and as shown in Fig. 5, the administration of the
IRAP-Myc gene in an adenoviral vector after balloon injury was
able to significantly limit the degree of neointimal thickening.
Immunohistochemical analysis with an anti-Myc antibody was
readily able to detect IRAP-Myc protein expression 14 days
postinjury (Fig. 5B Inset). An insertless adenoviral vector served
as a control, and as shown in Fig. 5A there was no apparent effect
of the adenovirus on neointimal thickening (Fig. 5), nor did the
Myc antibody exhibit a Myc signal in these tissue sections (Fig.
5A Inset). These data suggest that the expression of IRAP during
the response to injury is able to significantly impair the devel-
opment of a neointima in the rat.
Discussion
The biological significance of nonclassical export of signal
peptideless proteins has been difficult to access, because in vitro
methods using established cell lines that are amenable to stable
transfection were required to establish the pathways for release
(18, 21). This issue was complicated further by the absence of
data in vivo to confirm the in vitro mechanisms involved in the
nonclassical release of signal peptideless polypeptides. Although
we recently identified a Cu2-dependent mechanism responsible
for stress-induced release of the signal peptideless polypeptides
IL-1 and FGF1 using established and stably transfected human
and murine cell lines (19, 20), the biological significance of these
observations was not readily apparent. Here we report the ability
of freshly isolated human PBM cells to use intracellular Cu2 for
the stress-induced release of the endogenous precursor and
mature forms of IL-1, and similar data were also obtained for
the stress-induced release of FGF1 (data not shown). Indeed,
this observation represents a previously uncharacterized post-
translational mechanism for the stress-induced release of signal
peptideless polypeptides from normal human diploid mononu-
clear cells and confirms our data from established cell lines (17,
19). We also provide additional evidence concerning the role of
extracellular IL-1 as a determinant in the development of
restenosis in vivo. We demonstrate that inhibition of the IL-1
receptor by the somatic gene transfer of the IRAP gene imme-
diately after vascular injury is able to attenuate the response to
injury in the arterial vessel wall significantly. It has been exten-
sively demonstrated that proinflammatory cytokines are induced
very early after vascular injury and may play a crucial role in the
attraction of mononuclear cells during the early stages of reste-
nosis and experimental arteriosclerosis (42). Indeed, the obser-
vation that polymorphism of the IRAP gene is associated with
reduced restenosis (43) is consistent with our data. It is also well
established that the prototype members of the IL-1 gene family
are potent inducers of the latent transcription factor NF-B,
which in turn may contribute to injury-induced lumen loss by the
induction of a more prominent inflammatory response (44).
Because (i) extracellular IL-1 seems important for the re-
sponse to injury in vivo and (ii) Cu2 mediates the stress-induced
release of IL-1 and FGF1 from human PBM cells in vitro, we
suggest that efficient Cu2 chelation may be an approach for
management of arterial restenosis. Indeed, our data suggest that
the Cu2 chelator TTM is able to attenuate the development of
neointimal thickening significantly and is able to promote the
rapid reendothelialization of the denuded area. We further
suggest that the reduced response to injury in the TTM-treated
animals may be due to a repression of the infiltration of the vessel
wall with either blood- andor tissue-derived macrophages dur-
ing the immediate-early stages in the development of the vas-
cular response to injury. Indeed, the inhibition of mononuclear
cell recruitment to mechanically injured arteries that are devoid
of endothelium may also limit the delivery of essential cytokines
and growth factors responsible for the initiation of migration of
the vascular smooth muscle cell, a prerequisite for the develop-
ment of a neointima (6, 45). Although a wide variety of growth
factors and cytokines have been implicated as regulators of cell
migration within the vasculature (46, 47), the potential regula-
tory function of the FGF family members has been described
extensively (3, 48). Indeed, the introduction by somatic gene
transfer of an engineered form of FGF1 to force secretion of
this signal peptideless polypeptide through the endoplasmic
reticulum-Golgi apparatus resulted in an exaggeration of vascu-
lar smooth muscle cell migration and proliferation as well as the
formation of a prominent neointimal angiogenic response (2).
Because we observed a significant decrease in the immuno-
histochemical staining for FGF1, and IL-1 in the TTM-treated
rats compared with controls and Cu2-mediated heterotetramer
formation between S100A13 and either IL-1 or FGF1 is
responsible for their release in response to stress (19, 20), we
suggest that the attenuation of the restenotic response may have
been due to the ability of TTM to inhibit the release of IL-1 and
FGF1 in vivo. This observation is consistent with the ability of
TTM to inhibit the release of IL-1 and FGF1 from not only
NIH 3T3 cells but also human U937 cells (19, 20) and PBM cells
in vitro. Thus, these observations reinforce the premise that
intracellular Cu2 may play a key regulatory role in the nontra-
ditional export of signal-less polypeptides in vivo and that
effective drug-induced Cu2 chelation may be an innovative
approach for treating stress-dependent pathologies involving the
function of IL-1, FGF1, or both including cancer (27, 49),
because TTM has been shown to be an effective antiangiogenic
agent in vivo (27, 28). Likewise, recent studies have also sug-
gested that Cu2 chelation may represent an alternative ap-
proach to the management of -amyloid deposition in a trans-
genic mouse model of Alzheimer’s disease. Because IL-1
expression is enhanced significantly in the brains of Alzheimer’s
disease patients (50) and is able to induce the expression of the
-amyloid precursor gene in human endothelial cells in vitro (51),
the therapeutic effect of Cu2 chelators in Alzheimer’s pathol-
ogy may be due to their ability to inhibit the release of IL-1.
It is noteworthy that a major difference between the response
to injury in the control, the IRAP gene transfer, and TTM-
treated arteries was the apparent ability of vascular endothelial
cells to establish reparation of the denuded area. Although we
do not know the mechanism used by the TTM-treated animals
to repair the denuded area, it is unlikely that IL-1 and FGF1
play a role in the promotion of this response. However, because
IL-1 is able to repress endothelial cell migration (52), the
Fig. 5. The effects of adenoviral IRAP gene transfer on the formation of
neointima thickening in the rat. An adenoviral construct encoding a Myc-
tagged IRAP sequence was administered at the day of the balloon injury as
described in Methods. The administration of an insertless adenovirus served as
control. Representative cross sections from the carotid artery of the adenoviral
IRAP (B) and insertless adenoviral control (A) groups were stained with he-
matoxylineosin. (Magnification,10.) (Insets) Expression of the Myc epitope
tag (Myc-IRAP) was evaluated by anti-Myc immunohistochemical analysis.
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absence of IL-1 may enable another angiogenic factor to
function in a more astute manner. Because the vascular smooth
muscle cell is a rich source of vascular endothelial growth factor
(VEGF) (45) and VEGF is a prominent chemotactic signal for
the endothelial cell, it will be interesting to determine whether
members of the VEGF gene family are involved in the reparative
process.
Our data also suggest the absence of pS in injured tissue after
Cu2-chelation therapy. This may be an important component of
the nonclassical pathways of protein export and in our system
may involve the well described function of members of the S100
gene family as binding proteins for acidic phospholipids includ-
ing pS (53). In addition, recent evidence has demonstrated that
a hallmark of stress-induced cell injury may be the translocation
of pS to the outer leaflet of the plasma membrane (54). Further,
the absence of pS expression in the artery of TTM-treated rats
may also be a function of the antioxidant potential of the Cu2
chelator, which may also repress the effect of reactive oxygen
species at the place of injury. Reactive oxygen species are
thought to induce pS translocation either through the oxidation
of thiol-containing transport molecules or by the peroxidation of
lipids (54). Because our anti-pS monoclonal antibody specifically
recognizes the loss of pS asymmetry in the plasma membrane in
activated platelets and possibly in the injured vasculature as well,
this reagent may provide a tool for the visualization and perhaps
targeting of cells undergoing stress-induced responses in vivo.
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